Evogene (EVGN) Projected to Post Quarterly Earnings on Tuesday

Evogene (NASDAQ:EVGN) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 19th. Analysts expect the company to announce earnings of ($0.63) per share and revenue of $0.93 million for the quarter.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings results on Wednesday, May 21st. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.12. Evogene had a negative net margin of 224.82% and a negative return on equity of 102.40%. The company had revenue of $2.44 million for the quarter, compared to analyst estimates of $4.42 million.

Evogene Price Performance

NASDAQ:EVGN opened at $1.35 on Friday. The company has a market cap of $7.25 million, a PE ratio of -0.50 and a beta of 1.59. Evogene has a one year low of $0.95 and a one year high of $4.18. The firm’s 50 day simple moving average is $1.36 and its 200 day simple moving average is $1.30.

Hedge Funds Weigh In On Evogene

An institutional investor recently raised its position in Evogene stock. Jane Street Group LLC boosted its holdings in Evogene Ltd. (NASDAQ:EVGN) by 58.0% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 33,732 shares of the biotechnology company’s stock after buying an additional 12,387 shares during the quarter. Jane Street Group LLC owned 0.63% of Evogene worth $42,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 10.40% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Alliance Global Partners raised shares of Evogene to a “strong-buy” rating in a report on Monday, August 11th. Lake Street Capital set a $3.50 target price on shares of Evogene and gave the company a “buy” rating in a research note on Thursday, May 22nd. Finally, Wall Street Zen assumed coverage on shares of Evogene in a research note on Wednesday, May 21st. They set a “sell” rating on the stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.